Novel compounds as CK2 inhibitors for disease treatment
Summary
The USPTO has published a patent application (US20260085062A1) for novel compounds identified as CK2 inhibitors. These compounds are intended for the treatment and prevention of various diseases, including cancer, viral infections, and neurodegenerative disorders. The application details specific chemical structures and their potential pharmaceutical uses.
What changed
This document is a published patent application from the USPTO detailing novel compounds designed to inhibit Casein Kinase 2 alpha (CK2α). The application, US20260085062A1, describes specific chemical structures (Formula I) and their potential therapeutic applications in treating diseases such as cancer, viral infections, inflammation, diabetes, and neurodegenerative conditions. It also covers pharmaceutical compositions containing these compounds.
As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in drug discovery within the pharmaceutical sector. Companies involved in oncology, virology, and neurology research may find this application relevant for competitive intelligence and R&D strategy.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NOVEL COMPOUNDS AS CK2 INHIBITORS
Application US20260085062A1 Kind: A1 Mar 26, 2026
Inventors
Paul Glossop, Marko Juhana Hyvonen, Paul Brear, David Robert Spring
Abstract
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
CPC Classifications
C07D 403/14 A61K 31/416 A61K 31/4196 A61K 31/422 A61K 31/4245 A61K 31/433 A61K 31/4439 A61K 31/444 A61K 31/501 C07D 231/56 C07D 401/04 C07D 401/14 C07D 403/04 C07D 403/12 C07D 405/04 C07D 413/04 C07D 413/14 C07D 417/04 C07D 471/04
Filing Date
2023-09-08
Application No.
19109724
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.